Abstract 1070P
Background
Little is known about outcomes of adjuvant-treated melanoma patients beyond the clinical trial setting. Since 2019, adjuvant-treated melanoma patients have been registered in the DMTR, a population-based registry to monitor the quality and safety of melanoma care in the Netherlands. This study aims to describe treatment patterns, relapse, and toxicity rates of adjuvant-treated melanoma patients beyond the clinical trial setting.
Methods
Analyses were performed on adjuvant-treated melanoma patients included in the DMTR. Descriptive statistics were used to analyze patient-, and treatment characteristics. A baseline registration completeness analysis was performed, and an analysis on trial eligibility in clinical practice patients. Recurrence-free survival (RFS) at 12-months was estimated with the Kaplan-Meier method.
Results
A total of 683 patients treated were treated with adjuvant systemic therapy. The majority (93.9%) of these patients were treated with anti-PD-1. RFS at 12-months was 69.7% (95% CI, 65.8-73.9) with a median follow-up of 12.2 months. Factors associated with RFS were stage of disease and Breslow thickness. Eighteen percent of the anti-PD-1-treated patients developed grade ≥3 toxicity. Sixty-one percent of patients prematurely discontinued anti-PD-1 therapy.
Conclusions
Adjuvant anti-PD-1 treatment of resected stage III/IV melanoma in daily practice showed higher toxicity rates and more frequent premature discontinuation but similar RFS rates compared to trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C.U. Blank: Financial Interests, Institutional, Research Grant, Outside this work: Novartis; Financial Interests, Institutional, Research Grant, Outside this work: Bristol-Myers Squibb; Financial Interests, Institutional, Research Grant, Outside this work: NanoString; Financial Interests, Personal, Advisory Board: Bristol-Myers Squibb; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: GlaxoSmithKline; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Lily; Financial Interests, Personal, Advisory Board: GenMab; Financial Interests, Personal, Advisory Board: Pierre Fabre; Financial Interests, Personal, Ownership Interest: Uniti Cars; Financial Interests, Personal, Ownership Interest: Neon Therapeutics; Financial Interests, Personal, Ownership Interest: FortySeven. A.J.M. Van den Eertwegh: Other, Institutional, Advisory Role: Bristol-Myers Squibb; Other, Institutional, Advisory Role: MSD; Other, Institutional, Advisory Role: Roche; Financial Interests, Institutional, Research Grant, Outside this work: Roche. M. Boers-Sonderen: Other, Institutional, Advisory Role: Pierre Fabre; Other, Institutional, Advisory Role: MSD; Other, Institutional, Advisory Role: Novartis. E. Kapiteijn: Financial Interests, Institutional, Advisory Role: Amgen; Financial Interests, Institutional, Advisory Role: Bristol-Myers Squibb; Financial Interests, Institutional, Advisory Role: Novartis ; Financial Interests, Institutional, Advisory Role: Merck; Financial Interests, Institutional, Advisory Role: Pierre Fabre; Financial Interests, Institutional, Research Grant, Outside this work: Bristol-Myers Squibb. J.W.B. de Groot: Financial Interests, Institutional, Advisory Role: Bristol-Myers Squibb; Financial Interests, Institutional, Advisory Role: Novartis; Financial Interests, Institutional, Advisory Role: Pierre Fabre; Financial Interests, Institutional, Advisory Role: Servier; Financial Interests, Institutional, Advisory Role: MSD. J.B.A.G. Haanen: Financial Interests, Institutional, Advisory Role: Amgen; Financial Interests, Institutional, Advisory Role: AstraZeneca; Financial Interests, Institutional, Advisory Role: Bayer; Financial Interests, Institutional, Advisory Role: Bristol-Myers Squibb; Financial Interests, Institutional, Advisory Role: Celsius Therapeutics; Financial Interests, Institutional, Advisory Role: GSK; Financial Interests, Institutional, Advisory Role: Immunocore; Financial Interests, Institutional, Advisory Role: Ipsen; Financial Interests, Institutional, Advisory Role: MSD; Financial Interests, Institutional, Advisory Role: Merck; Financial Interests, Institutional, Advisory Role: Serono; Financial Interests, Institutional, Advisory Role: Novartis; Financial Interests, Institutional, Advisory Role: Neon Therapeutics; Financial Interests, Institutional, Advisory Role: Pfizer; Financial Interests, Institutional, Advisory Role: Roche/Genentech; Financial Interests, Institutional, Advisory Role: Sanofi; Financial Interests, Institutional, Advisory Role: Seattle Genetics ; Financial Interests, Institutional, Research Grant, Outside this work: Novartis; Financial Interests, Institutional, Research Grant, Outside this work: Bristol-Myers Squibb; Financial Interests, Institutional, Research Grant, Outside this work: Neon Therapeutics; Financial Interests, Institutional, Research Grant, Outside this work: MSD. G.A. Hospers: Financial Interests, Institutional, Advisory Role: Amgen; Financial Interests, Institutional, Advisory Role: Bristol-Myers Squibb; Financial Interests, Institutional, Advisory Role: Roche; Financial Interests, Institutional, Advisory Role: MSD; Financial Interests, Institutional, Advisory Role: Pfizer; Financial Interests, Institutional, Advisory Role: Novartis; Financial Interests, Institutional, Research Grant, Outside this work: Bristol-Myers Squibb; Financial Interests, Institutional, Research Grant, Outside this work: Seerave. A.A.M. Van der Veldt: Financial Interests, Institutional, Advisory Role: Bristol-Myers Squibb; Financial Interests, Institutional, Advisory Role: MSD; Financial Interests, Institutional, Advisory Role: Roche; Financial Interests, Institutional, Advisory Role: Novartis; Financial Interests, Institutional, Advisory Role: Pierre Fabre; Financial Interests, Institutional, Advisory Role: Pfizer; Financial Interests, Institutional, Advisory Role: Sanofi; Financial Interests, Institutional, Advisory Role: Ipsen; Financial Interests, Institutional, Advisory Role: Eisai. H.M. Westgeest: Financial Interests, Institutional, Other: Ipsen; Financial Interests, Personal, Other: Roche; Financial Interests, Personal, Other: Astellas. K. Suijkerbuijk: Financial Interests, Institutional, Advisory Role: Bristol-Myers Squibb; Financial Interests, Institutional, Advisory Role: MSD; Financial Interests, Institutional, Other: Novartis ; Financial Interests, Institutional, Other: Pierre Fabre; Financial Interests, Institutional, Other: Roche. All other authors have declared no conflicts of interest.